lonapegsomatropin · Skytrofa

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Growth Hormone Deficiency

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
CN
  • Pediatric growth hormone deficiency (by VISEN, Chinese brand LongPei)
Product first approved 2026itiger.com
EU
  • Growth failure in children and adolescents aged 3 to 18 years due to growth hormone deficiency
Product first approved 2022EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Growth Hormone Deficiency
NCT03344458 · Ascendis Pharma A/S
2017-12-19 – 2023-02-21 · Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
What this study did
NCT04326374 · Visen Pharmaceuticals (Shanghai) Co., Ltd.
2019-12-30 – 2022-04 · Growth Hormone Deficiency, Endocrine System Diseases, Hormones, Pituitary Diseases, Pituitary Disease, Anterior
What this study did
NCT03305016 · Ascendis Pharma Endocrinology Division A/S
2017-11-13 – 2019-03-19 · Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
What this study did
Other / comorbidity
NCT07924059 · Ascendis Pharma A/S
2026-11 – 2029-09 · Achondroplasia
What this study did
NCT07221851 · Ascendis Pharma A/S
2025-12-12 – 2029-03 · Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
What this study did
Phase 2 (3)
Growth Hormone Deficiency
NCT01247675 · Ascendis Pharma A/S
2010-11 – 2011-05 · Adult Growth Hormone Deficiency
What this study did
Other / comorbidity
NCT05690386 · Ascendis Pharma Endocrinology Division A/S
2023-02-15 – 2027-12 · Turner Syndrome
What this study did
NCT06433557 · Ascendis Pharma Growth Disorders A/S
2024-07-26 – 2027-11 · Achondroplasia
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Growth Hormone Deficiency: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lonapegsomatropin (Skytrofa): this drugApprovedProtein / enzyme therapeuticGrowth hormone receptorPartial signalFeatured results are safety and non-efficacy only in this race
Somatrogon (NGENLA)ApprovedProtein / enzyme therapeuticGrowth hormone receptorPartial signal
NCT03831880: Overall life interference total score (DCOA 1), crossover: weekly somatrogon 8.63 vs daily Genotropin 24.13; difference -15.49 (95% CI -19.71 to -11.27), p<0.0001 (CT.gov posted results).
Somatropin (Serostim)
Approved(overall)
Protein / enzyme therapeuticGrowth hormone receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Somatropin (Jintropin)
Phase 3(overall)
Biologic (subtype unspecified)Growth hormone receptor
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Skytrofa (lonapegsomatropin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
February 2028 (1)
Phase 3Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at DeliveryRecruiting
Est. primary completion 2028-02 · NCT07221851 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3AchondroplasiaNot yet recruiting
Est. primary completion 2028-09 · NCT07924059 · CT.gov ↗
What to watch

See the full readout calendar ↗